News stories about Idera Pharmaceuticals (NASDAQ:IDRA) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Idera Pharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.2514575802345 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

Shares of Idera Pharmaceuticals (IDRA) opened at 1.61 on Tuesday. The stock’s 50 day moving average is $2.25 and its 200-day moving average is $1.96. Idera Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $2.87. The firm’s market cap is $240.91 million.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03). Idera Pharmaceuticals had a negative return on equity of 61.09% and a negative net margin of 300.63%. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.20 million. On average, equities analysts predict that Idera Pharmaceuticals will post ($0.48) EPS for the current fiscal year.

IDRA has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. ValuEngine raised shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. BidaskClub lowered shares of Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $4.00 price target on shares of Idera Pharmaceuticals in a research report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $5.75.

COPYRIGHT VIOLATION WARNING: This story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://theolympiareport.com/2017/10/31/idera-pharmaceuticals-idra-earning-somewhat-favorable-press-coverage-analysis-shows.html.

In related news, Director Bros. Advisors Lp Baker purchased 8,000,000 shares of the business’s stock in a transaction dated Thursday, October 26th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $12,000,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 30.29% of the stock is owned by corporate insiders.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Insider Buying and Selling by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.